| Trial ID: | L6717 |
| Source ID: | NCT01144728
|
| Associated Drug: |
Glimepiride + Metformin
|
| Title: |
Initiation and Titration of Amaryl
|
| Acronym: |
AMIT KZ
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GLIMEPIRIDE + METFORMIN
|
| Outcome Measures: |
Primary: Glycolysated Haemoglobin (HbA1c), From baseline to Month 4|Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%, Month 4|Evolution of Fasting Plasma Glucose (FPG), From baseline to Months 4 | Secondary: Post Prandial Plasma Glucose (PPPG), Month 4|Number of patients for each start dose, At baseline|Number of patients with different final doses, Month 4|Rate of Symptomatic Hypoglycemia, During treatment period (4 months)|Change in Weight, Month 4
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
172
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-05
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2011-01-31
|
| Locations: |
Sanofi-Aventis Administrative Office, Almaty, Kazakhstan
|
| URL: |
https://clinicaltrials.gov/show/NCT01144728
|
